Natalizumab treatment reduces L-selectin (CD62L) in CD4(+) T cells

BACKGROUND: The purpose of this research was to validate the low expression of L-selectin (CD62L) in natalizumab (NTZ)-treated patients. CD62L is involved in rolling and transmigration of leukocyte cells. A correlation between CD62LCD4(+) T cells low expression and progressive multifocal leukoenceph...

Descripción completa

Detalles Bibliográficos
Autores principales: Spadaro, Michela, Caldano, Marzia, Marnetto, Fabiana, Lugaresi, Alessandra, Bertolotto, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532246/
https://www.ncbi.nlm.nih.gov/pubmed/26259673
http://dx.doi.org/10.1186/s12974-015-0365-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532246/
https://www.ncbi.nlm.nih.gov/pubmed/26259673
http://dx.doi.org/10.1186/s12974-015-0365-x

Ejemplares similares